46 / 47
46
Delta-9-tetrahydrocannabinol
effects
in
schizophrenia:
implications
for
cognition,
psychosis, and addiction. Biol Psychiatry
2005;57:594-608.
60. Kamali M, Kelly L, Gervin M, Browne S, Larkin
C, O'Callaghan E. The prevalence of comorbid
substance misuse and its influence on suicidal
ideation among in-patients with schizophrenia.
Acta Psychiatr Scand 2000;101:452-6.
61. Caldwell CB, Gottesman, II. Schizophrenics kill
themselves too: a review of risk factors for suicide.
Schizophr Bull 1990;16:571-89.
62. Palmer BA, Pankratz VS, Bostwick JM. The
lifetime risk of suicide in schizophrenia: a
reexamination. Arch Gen Psychiatry 2005;62:247-53.
63. Large M, Smith G, Sharma S, Nielssen O, Singh
SP. Systematic review and meta-analysis of the
clinical factors associated with the suicide of
psychiatric in-patients. Acta Psychiatr Scand
2011;124:18-29.
64. Hor K, Taylor M. Suicide and schizophrenia: a
systematic review of rates and risk factors. J
Psychopharmacol 2010;24(4 Suppl):81-90.
65. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ.
Schizophrenia and suicide: systematic review of
risk factors. Br J Psychiatry 2005;187:9-20.
66. Meltzer HY, Alphs L, Green AI, Altamura AC,
Anand R, Bertoldi A, et al. Clozapine treatment for